Faron’s Post

Promising therapies, particularly JAK inhibitors, as game-changers in the treatment landscape. The FDA has approved baricitinib (Olumiant) and ritlecitinib (Litfulo) for AA, showcasing significant regrowth in clinical trials. The future looks hopeful, with ongoing trials exploring other JAK inhibitors and combination therapies. Notably, the emerging therapies address not only the physical aspects but also the emotional impact of AA. #Alopecia Areata #Hairloss #Hair growth #patientsupport #skincrestclinic

Multiple Sclerosis Market Assessment 2034 | Multiple Sclerosis Therapies, FDA Approval, Clinical trials, Prevalence, Treatment Algorithms and Companies by DelveInsight | Immune Response BioPharma: Multiple Sclerosis Market As per DelveInsight, the Multiple Sclerosis Market is anticipated to grow immensely in the coming years owing to the launch of upcoming therapies and the increase in the incident population of Multiple Sclerosis in the 7MM. DelveInsight’s … Continue reading → #Business #Europe #HealthMedicine #PharmaceuticalsBiotech #US

Approximately 6.7 million Americans over 20 years old have #heartfailure, which is expected to rise to 8.5 million Americans by 2030. Join us at OM1, Inc. Feb 12-16th for Heart Failure week.  Pharma companies are paying anywhere from $75K to $5M per year to acquire datasets that can speed up drug discovery, clinical trial design, and regulatory reporting. Top 10 Pharma uses OM1’s Heart Failure (HF) dataset to drive insights from both observed and amplified endpoints such as LVEF and NYHA. OM1 helps to fill crucial gaps not readily available in RWD through extraction of clinical notes by machine learning and extraction. Including this information in the HF data set can greatly improve assessment of the patient journey and the evaluation of treatment outcomes in the HF patient population and within different clinical phenotypes. The estimation model for NYHA (eNYHA) has been validated and a methodology publication is in progress. Interested in learning more? 📍 https://lnkd.in/edaasdns #clinicaltrials #heartfailure #HFWeek2024 #hf

An indisputable fact in any Alzheimer's reasearch area is the importance of an early detection.

💥There were 9 Key Digital Therapeutics (DTx) Developments in April 2024 🌅See infographic slide below with the summaries, along with therapeutic area and news category key 🧠4 in Mental Health and 💗3 in Cardiovascular show these areas are still dominating the development focus ✅4 approvals (3 FDA and one in India) #DigitalHealth #DTx

In a Phase III trial, the novel drug achieved near-complete stabilisation of TTR proteins in ATTR-CM patients #drugdevelopment #clinicaltrials #EPRTalks

We just published a research update on Immuron (ASX:IMC, A$0.073): Progressing fast with clinical trials. The company has made significant progress in recent months with clinical studies, the results of which will be published later in 2024. We reiterate our valuation of Immuron as first outlined in our initiation report – at A$0.25 per share in a base case scenario and A$0.35 per share in an optimistic (bull) case scenario. #immuron #asx

Approximately 6.7 million Americans over 20 years old have #heartfailure, which is expected to rise to 8.5 million Americans by 2030. Join us at OM1, Inc. Feb 12-16th for Heart Failure week. Pharma companies are paying anywhere from $75K to $5M per year to acquire datasets that can speed up drug discovery, clinical trial design, and regulatory reporting. Top 10 Pharma uses OM1’s Heart Failure (HF) dataset to drive insights from both observed and amplified endpoints such as LVEF and NYHA. OM1 helps to fill crucial gaps not readily available in RWD through extraction of clinical notes by machine learning and extraction. Including this information in the HF data set can greatly improve assessment of the patient journey and the evaluation of treatment outcomes in the HF patient population and within different clinical phenotypes. The estimation model for NYHA (eNYHA) has been validated and a methodology publication is in progress. Interested in learning more? 📍 https://lnkd.in/edaasdns #HFWeek2024 #heartfailure #HFWeek2024 #hearthealth

FibroBiologics (Nasdaq: FBLG) has entered a master services agreement with Charles River Laboratories to develop and manufacture cell-based therapies for chronic diseases. Charles River Global Manufacturing corporate senior vice-president Kerstin Dolph stated: “Charles River’s work with FibroBiologics is part of a larger commitment to supporting next-generation regenerative medicine through the adoption of innovative therapies. We are excited to collaborate with FibroBiologics and support the development of a therapy that has the potential to transform patient care for those impacted by diabetic foot wounds.” Click here for the full article - https://lnkd.in/d2X23nan #pharma #drugmanufacturing #chronicdiseases #celltherapy #regenerativemedicine #diabetes

Recently, Inventiva announced positive results of its interim analysis of the Phase II, Proof-of-Concept clinical trial, LEGEND, evaluating lanifibranor in combination with empagliflozin in patients with MASH/NASH and poorly controlled Type 2 Diabetes (T2D). The study achieved the primary efficacy endpoint. Lanifibranor is an orally-available small molecule pan PPAR agonist with a -wellbalanced- activation of PPARα and PPARδ, and a partial activation of PPARγ. Lanifibranor acts to induce anti fibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body. Chemenu team is always committed to developing more compounds for drug discovery. Here come the related building blocks we can provide: https://lnkd.in/gxNGFuzH 👇 #Chemenu #Inventiva #LEGEND #lanifibranor #empagliflozin #MASH/NASH #Type2Diabetes #endpoint #PPAR #antifibrotic #anti-inflammatory #vascularandmetabolicchanges #drugdiscovery #buildingblocks